Search News
| 61.48 Delayed Data As of Sep 18 |  +0.18 / +0.29%Today’s Change | 49.96 Today|||52-Week Range 70.05 | +0.33% Year-to-Date |
| Previous close | 61.30 |
| Today’s open | 61.18 |
| Day’s range | 61.13 - 61.66 |
| Volume | 3,703,572 |
| Average volume (3 months) | 6,172,726 |
| Market cap | $100.0B |
| Earnings growth (last year) | -76.98% |
| Earnings growth (this year) | +19.56% |
| Earnings growth (next 5 years) | +11.70% |
| Revenue growth (last year) | +6.94% |
| P/E ratio | 256.2 |
| Price/Sales | 4.87 |
| Price/Book | 8.48 |
| Today’s change | Today’s % change | |
|---|---|---|
| GSKGlaxoSmithKline | +0.42 | +1.07% |
| AZNAstraZeneca | -0.07 | -0.19% |
| SNYSanofi | +0.21 | +0.48% |
| NVONovo Nordisk | -0.21 | -0.44% |
| Next reporting date | October 25, 2018 |
| EPS forecast (this quarter) | $0.89 |
| Annual revenue (last year) | $20.8B |
| Annual profit (last year) | $1.0B |
| Net profit margin | 4.85% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman & Chief Executive Officer Giovanni Caforio |
CFO, EVP & Head-Global Business Operations Charles A. Bancroft |
Corporate headquarters New York, New York |
